Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nicotine letter

This article was originally published in The Tan Sheet

Executive Summary

The "public health imperative" that led FDA to prohibit sale of nicotine lollipops "should lead to the same swift and decisive action with regard" to other unconventional nicotine products, 11 public health groups assert in April 19 letter to FDA. "While we recognize that no two products are exactly alike," agency's purview over novel nicotine delivery vehicles is "as strong as the authority that it exercised to prohibit the sale of nicotine lollipops," letter states. FDA recently targeted four Internet pharmacies selling nicotine pops, lip balms (1"The Tan Sheet" April 15, 2002, p. 7). Letter, signed by health groups such as AMA, AHA, Campaign for Tobacco-Free Kids, references their Dec. 18 petition urging FDA to regulate nicotine lozenges, water as either foods or drugs (2"The Tan Sheet" Dec. 24, 2001, p. 5)...

You may also be interested in...

Nicotine Lollipops Active Ingredient Nicotine Salicylate “Illegal” – FDA

The Professional Compounding Centers of America is urging its members to switch from nicotine salicylate to nicotine polacrilex when compounding lollipops to help patients quit smoking

Ariva Tobacco Lozenges Outside FDA Purview, Marketer Maintains

Allegations Ariva tobacco lozenges make implicit drug claims are without legal merit, Star Scientific maintains in response to a Dec. 18 1petition jointly filed by 18 public health organizations. The petition urges FDA to regulate the lozenges as either a food or a drug

FDA OK’s Insomnia Treatment Through Software Pre-Cert Program

Pear Therapeutics’ Somryst insomnia treatment tool has become the first FDA-cleared product that was reviewed through the agency’s Software Precertification Pilot Program.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts